# An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis

> **NCT02407223** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 356 (actual)

## Conditions studied

- Nonradiographic Axial Spondylitis, Ankylosing

## Interventions

- **DRUG:** Group 1: Placebo
- **DRUG:** Group 2: Ustekinumab 45 mg
- **DRUG:** Group 3: Ustekinumab 90 mg

## Key facts

- **NCT ID:** NCT02407223
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-13
- **Primary completion:** 2017-09-26
- **Final completion:** 2017-09-26
- **Target enrollment:** 356 (ACTUAL)
- **Why stopped:** This study was stopped because ustekinumab did not achieve key endpoints in a related study. The safety profile was consistent with past ustekinumab studies.
- **Last updated:** 2019-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02407223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02407223, "An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02407223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*